540
Participants
Start Date
December 8, 2022
Primary Completion Date
April 30, 2025
Study Completion Date
March 31, 2026
Cabotegravir/Rilpivirine
injectable long-acting cabotegravir 600mg + long-acting rilpivirine 900mg administered every 2 months
Antiretroviral
Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
Jaramogi Oginga Odinga Teaching & Referral Hospital, Kisumu
Kenyatta National Hospital, Nairobi
Desmond Tutu Health Foundation, Cape Town
CAPRISA, Durban
Entebbe Grade A Hospital, Entebbe
JCRC Fort Portal, Fort Portal
Infectious Diseases Institute, Kampala
Collaborators (1)
Janssen Pharmaceuticals
INDUSTRY
MRC/UVRI and LSHTM Uganda Research Unit
OTHER